Synthesis and Application of a Novel Organic Arsenic

By precisely coupling low-toxicity organic arsenic pharmacophores with bioactive molecules, novel organic arsenic compounds are synthesized, solving the problems of high toxicity and narrow application range of existing organic arsenic drugs. This achieves a low-toxicity, high-activity, broad-spectrum anticancer effect and expands the therapeutic range of arsenic agents.

CN123106769APending Publication Date: 2026-11-17高明章
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611461541.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies lack a systematic design strategy to effectively couple low-toxicity organic arsenic pharmacophores with specific bioactive molecules, making it impossible to develop novel organic arsenic drugs that combine low toxicity, high activity, and broad-spectrum anticancer potential. Furthermore, traditional inorganic arsenic compounds such as ATO have a narrow therapeutic window, high toxicity, and limited application scope.

Method used

Through innovative molecular design, a series of novel organoarsenic compounds, such as GMCTC, GMRA, and the targeting cyclic peptide c(RGDfC)/c(RGDyC), were synthesized by covalently coupling the low-toxicity organoarsenic pharmacophore (dimethylarsyl) to a molecular backbone with definite biological activity via a stable thioether bond, achieving multi-target synergistic effects.

Benefits of technology

It significantly reduces the systemic toxicity of arsenic-based compounds, maintains or enhances anticancer activity, and expands the anticancer spectrum from acute promyelocytic leukemia to a variety of malignant tumors such as lymphoma, prostate cancer, colon cancer, and lung cancer, overcoming the limitations of traditional inorganic arsenic agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106769A_ABST
    Figure CN123106769A_ABST
Patent Text Reader

Abstract

This invention relates to the synthesis and application of novel organic arsenic compounds, belonging to the field of pharmaceutical chemistry. Through molecular design, a series of novel organic arsenic compounds were synthesized by covalently coupling a pharmacophore with a stable thioether bond to a specific bioactive molecule, thereby reducing toxicity. The core technology lies in using dimethyl arsenyl chloride as a key intermediate, reacting it with a thiol-containing bioactive molecule to obtain the target product. The compounds of this invention significantly reduce the toxicity of traditional inorganic arsenic agents and exhibit broad-spectrum and potent anticancer activity. In vitro experiments show that representative compounds GMCTC, GMRA, GMYC, and GMFC exhibit nanomolar to micromolar inhibitory activity against various leukemia cells and solid tumor cells. The anticancer spectrum has been successfully expanded from APL to various malignant tumors such as lymphoma, prostate cancer, and lung cancer, providing new candidate compounds for the development of highly effective and low-toxicity anticancer drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical chemistry, specifically to the synthesis and application of a novel organic arsenic compound. Background Technology

[0002] Malignant tumors, especially leukemia, are a serious global public health problem threatening human health. According to The Lancet, in 2023, there were 18.5 million new cancer cases and 10.4 million deaths worldwide. Leukemia has the highest incidence rate among children and adolescents, with approximately 487,000 new cases and 305,000 deaths globally in 2022, highlighting a severe situation.

[0003] Acute promyelocytic leukemia (APL) was once one of the most dangerous types of leukemia, with an extremely high mortality rate. Currently, the standard clinical treatment for APL is a targeted therapy regimen of all-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) (the "Shanghai regimen"). While this regimen has significantly improved patient survival rates, it still has inherent limitations. First, ATO (commonly known as arsenic trioxide), one of the core drugs, is highly toxic, has a narrow therapeutic window, significant off-target effects, and can damage multiple organs, including the cardiovascular system, liver, kidneys, and nervous system, limiting its clinical application. Second, ATO has limited efficacy against other types of leukemia besides APL and various solid tumors, greatly restricting its anti-cancer spectrum.

[0004] Although studies have shown that organic arsenic compounds are far less toxic than inorganic arsenic (e.g., the median lethal dose (LD50) of dimethylarsonic acid in mice). 50 The LD50 of ATO is 500 mg / kg. 50 The concentration of arsenic compounds is only 10 mg / kg, and the types of organic arsenic compounds that exist in nature are scarce and difficult to obtain directly. Current technologies lack systematic design strategies to effectively conjugate low-toxicity organic arsenic pharmacophores with specific bioactive molecules (especially those with targeted anticancer activity), thus failing to develop novel organic arsenic drugs that combine low toxicity, high activity, and broad-spectrum anticancer potential.

[0005] Therefore, there is an urgent need in this field for an innovative technical solution that can synthesize a series of novel organoarsenic compounds through rational molecular design. These compounds are designed to significantly reduce the toxicity of arsenic-based drugs while maintaining or enhancing their anticancer activity and increasing their anticancer targeting, and to expand their therapeutic scope from APL to a variety of hematologic malignancies and solid tumors such as lymphoma, prostate cancer, colon cancer, and lung cancer, in order to overcome the limitations of existing arsenic therapy. Summary of the Invention

[0006] In order to solve the problems of the prior art, the present invention provides a novel synthesis of organic arsenic and its application.

[0007] To solve the above-mentioned technical problems, the present invention is achieved through the following technical solution: Firstly, an organoarsenic compound or a pharmaceutically acceptable salt thereof, said compound having the structure shown in general formula (I):

[0008]

[0009] General Formula (I)

[0010] Where n is an integer from 0 to 10, and R1 is a C1-C20 alkyl group or a substituted alkyl group.

[0011] In one specific embodiment of the first aspect, R1 is selected from methyl, ethyl, propyl, isopropyl, or butyl.

[0012] In one specific embodiment of the first aspect, the compound is (S)-10-((dimethylarsenyl)thio)-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7] indo[1,2-b]quinoline-3,14(4H)-dione (GMCTC).

[0013] In one specific embodiment of the first aspect, the compound is a compound represented by general formula (II):

[0014]

[0015] General Formula (II)

[0016] Wherein, R1 is a C1-C20 alkyl group, or a substituted alkyl group. R is a C1-C20 alkylene chain, a substituted alkylene group, an aryl group or a substituted arylene group, or a derivative thereof.

[0017] In one specific embodiment of the first aspect, R1 is selected from methyl, ethyl, propyl, isopropyl, or butyl.

[0018] In one specific embodiment of the first aspect, the compound is methyl N-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)noni-2,4,6,8-tetraenoyl)-S-(dimethylarsyl)-L-cysteine ​​ester (GMRA).

[0019] In one specific embodiment of the first aspect, the compound is a compound represented by general formula (III):

[0020]

[0021] General Formula (III)

[0022] Where R represents C1-C20 alkyl or substituted alkyl; Cyclo-peptide represents a monocyclic peptide.

[0023] In one specific embodiment of the first aspect, the cyclic peptide is selected from the group consisting of the following sequences:

[0024] cyclo(Arg-Gly-Asp-D-Phe-Cys) [c(RGDfC)],

[0025] cyclo(Arg-Gly-Asp-D-Tyr-Cys) [c(RGDyC)],

[0026] cyclo(Arg-Gly-Asp-D-Phe-Lys(COCH2CH2SH)) [c(RGDfK(Mpa))],

[0027] cyclo(Arg-Gly-Asp-D-Phe-Lys(COCH2SH)) [c(RGDfK(COCH2SH))],

[0028] cyclo(Arg-Gly-Asp-D-Phe-Lys(Cys)) [c(RGDfK(Cys))].

[0029] In one specific embodiment of the first aspect, the compound has the structure shown in general formula (IV):

[0030]

[0031] General Formula (IV)

[0032] Wherein, R1 is a C1-C20 alkyl group or a substituted alkyl group; R2 is selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, amino, carboxyl, cyano, or nitro.

[0033] In one specific embodiment of the first aspect, R1 is selected from methyl, ethyl, propyl, isopropyl, or butyl; R2 is selected from hydrogen or hydroxyl.

[0034] In one specific embodiment of the first aspect, the compound is GMFC, GMYC.

[0035] In a second aspect, a method for preparing organoarsenic compounds of general formulas (I) to (IV) is provided, the method using dimethylarsine chloride as an arsenating agent, the dimethylarsine chloride being prepared by dissolving dimethylarsic acid in concentrated hydrochloric acid, reacting it with a mixture of hypophosphoric acid and hydrochloric acid, and then purifying it.

[0036] The third aspect concerns the use of the pharmaceutical composition described in the organic arsenic compound in the preparation of a medicament for treating cancer.

[0037] The cancers mentioned are selected from leukemia, lymphoma, lung cancer, skin cancer, prostate cancer, colorectal cancer, breast cancer, esophageal cancer, liver cancer, stomach cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, or cervical cancer.

[0038] The beneficial effects of this invention are as follows:

[0039] 1. This invention, through innovative molecular design, covalently couples a low-toxicity organic arsenic pharmacophore (dimethylarsyl) to a molecular backbone with definite biological activity via a stable thioether bond (-S-), successfully synthesizing a series of novel organic arsenic compounds of general formula (I). This core technology directly brings multiple significant technical effects: First, by utilizing the inherent low toxicity of organic arsenic compared to inorganic arsenic (such as arsenic trioxide), the systemic toxicity of arsenic-based compounds is fundamentally and significantly reduced. For example, the synthesis and application of the key intermediate dimethylarsyl chloride significantly improves the safety of the final product while maintaining high anticancer activity. Second, by precisely coupling the organic arsenic module with specific active molecules (such as the natural product derivative GMCTC, the retinoic acid derivative GMRA, and the targeted cyclic peptide c(RGDfC) / c(RGDyC)), multi-target synergistic effects are achieved. This design not only retains the pharmacological activity of the original parent molecule but also introduces a new mechanism for arsenic agents to induce cancer cell differentiation and apoptosis, thereby producing a synergistic anticancer effect.

[0040] 2. In vitro antitumor activity evaluation data fully confirm the above-mentioned technical effects. The compounds of this invention exhibit potent inhibitory activity at the nanomolar to micromolar levels against various hematological malignancies and solid tumors. For example, compound GMCTC shows strong inhibitory activity against IC50 in chronic myeloid leukemia K562 cells. 50 The IC50 value reached 0.5 μM, and it had an IC50 value of 0.5 μM against HCT-116 colon cancer cells. 50 The concentration was 1.1 μM; and the cyclic peptide conjugates GMYC and GMFC also showed excellent activity against various cell lines, including prostate cancer and leukemia. This indicates that the patented technology has successfully expanded the anticancer spectrum of organic arsenic drugs from the traditional acute promyelocytic leukemia (APL) to a variety of malignant tumors such as lymphoma, prostate cancer, colon cancer, lung cancer, and melanoma. It overcomes the core technical bottleneck of the narrow application range and high toxicity of traditional inorganic arsenic agents, and provides structurally diverse and effective candidate compounds for the development of novel targeted anticancer drugs with high efficacy and low toxicity. Attached Figure Description

[0041] Figure 1 This is a schematic diagram of the synthetic route for dimethylarsine chloride of the present invention.

[0042] Figure 2 This is a schematic diagram of the synthetic route of the compound GMCTC of this invention.

[0043] Figure 3 This is a schematic diagram of the synthetic route of the compound GMRA of this invention.

[0044] Figure 4 This is a schematic diagram illustrating the general formula for the synthesis of the cyclic peptide organic arsenic compound (GMFC / GMYC) of the present invention. Detailed Implementation

[0045] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0046] like Figures 1 to 4 shown.

[0047] Example 1, please refer to Figure 1 The diagram shows the synthesis of the compound dimethylarsane chloride (dimethylarsane chloride, dimethylarsane, chlorodimethylarsane, (CH3)2AsCl).

[0048] Dimethylarsine was supplied by Sigma-Aldrich. Dissolve 100 g of 0.72 mol (CH3)2As(O)OH in 120 mL of concentrated hydrochloric acid. In another container, thoroughly mix 210 g of hydrochloric acid and 95 g of 50% hypophosphoric acid. Add half of the H3PO2 / HCl mixture to the dimethylarsine / hydrochloric acid mixture. Stir the solution using a magnetic stirrer. The reaction mixture becomes cloudy; raise the temperature to 45°C. Sometimes gentle heating is necessary to maintain the reaction. Maintain the temperature at 40-45°C. If necessary, cool with an ice bath. Slowly add the remaining H3PO2 / HCl in small amounts to the reaction flask. After the addition is complete, allow the reaction flask to stand. Dimethylarsine chloride separates as a heavy, oily liquid below the aqueous layer. Separate the two immiscible liquid layers. Care must be taken to avoid contact between dimethylarsine chloride and skin. It can penetrate the skin, causing blisters to heal very slowly.

[0049] The heavier lower layer is dimethylarsine chloride, which is wet due to contact with water. It is dried with anhydrous calcium chloride, at least overnight. The dried compound is then transferred to a distillation apparatus. Purification is carried out by distillation under a nitrogen atmosphere. Its boiling point is 106–109°C. The resulting product is a clear, colorless liquid in 45–54% yield. It can be stored for a long time in a dry container. This liquid hydrolyzes very slowly.

[0050] Example 2, please refer to Figure 2 The following is an illustration of the synthesis of compound GMCTC ((S)-10-((dimethylarsenyl)thio)-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7] indene[1,2-b]quinoline-3,14(4H)-dione).

[0051] Preparation of compound HS20189-2:

[0052] A solution of (4S)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f] indene-3,6,10-trione (HS2089-1, 1.00 g, 3.80 mmol, 1.00 eq) and 2-amino-6-bromobenzaldehyde (760 mg, 3.80 mmol, 1.00 eq) was dissolved in acetic acid (40.0 mL) and hydrochloric acid (7.00 mL) and stirred at 130°C for 8 hours. The reaction was terminated by slow addition of water (50.0 mL), and the pH was then slowly adjusted to 8 with sodium bicarbonate. The mixture was then filtered to obtain a filter cake of (19S)-8-bromo-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]tetane-1(21),2,4,6,8,10,15(20)-heptaen-14,18-dione (1.42 g, crude), which was a white solid HS20189-2. Liquid chromatography-mass spectrometry (LCMS) [M+1] was then used. + = 427.1.

[0053] Preparation of compound HS20189-3:

[0054] (19S)-8-bromo-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20] icosico-1(21),2,4,6,8,10,15(20)-heptaen-14,18-dione (HS20189-2) (1.42 g, 3.32 mmol, 1.00 equivalent) and ethyl 3-thiopropionate (669 mg, 4.99 mmol) The mixture of dioxane (25.0 mL) containing 1.50 equivalences of methyl ethyl ether (ME), Pd2(dba)3 (304 mg, 332 μmol, 0.10 equivalences), Xantphos (385 mg, 665 μmol, 0.20 equivalences), and triethylamine (TEA) (1.01 g, 9.97 mmol, 1.39 mL, 3.00 equivalences) was degassed and purged three times with nitrogen, then stirred at 80 °C for 8 h under a nitrogen atmosphere. The reaction mixture was terminated by adding water (50.0 mL) at 25 °C and extracted with ethyl acetate (30.0 mL × 2). The combined organic layers were washed with brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by preparative high-performance liquid chromatography (prep-HPLC) (column: Waters Xbridge Prep OBD C18 150×40 mm×10 μm; mobile phase: [water (NH4HCO3)-acetonitrile]; B%: 25%-55%, 15 min) to give a yellow solid of ethyl 3-[[(19S)-19-ethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]docosa-1(21),2,4,6,8,10,15(20)-heptaen-8-yl]thio]propionate (500 mg, 991 μmol, 29.8% yield, 95.2% purity). LC-MS [M+1] was used for further purification. + = 481.3.

[0055] Preparation of compound HS20189:

[0056] An ethanol solution (3.00 mL) of sodium ethoxide (354 mg, 5.20 mmol, 5.00 eq) was slowly added at 25°C to a mixture of ethyl 3-[[(19S)-19-ethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentane[11.8.0.02,11.04,9.015,20]docosa-1(21),2,4,6,8,10,15(20)-heptaen-8-yl]thioalkyl]propionate (HS20189-3) (500 mg, 1.04 mmol, 1.00 eq) in ethanol (3.00 mL), and the resulting mixture was stirred at 25°C for 2 hours. Under nitrogen protection, the reaction mixture was quenched at 0°C by adding water (20.0 mL), and the mixture was concentrated under reduced pressure to remove the solvent. The mixture was dissolved in water (50 ml), extracted with ethyl acetate (50 ml × 2) to remove impurities, and then the pH of the aqueous phase was adjusted to 4 with solid citric acid (200 mg), followed by extraction with vinyl acetate (50 ml × 2). The combined organic layers were washed with brine (50 ml), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product (19S)-19-ethyl-19-hydroxy-8-thioalkyl-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]tetane-1(21),2,4,6,8,10,15(20)-heptaen-14,18-dione (HS20189), yielding a yellow oily product (350 mg, crude). LCMS [M+1] + = 381.1.

[0057] Preparation of compound GMCTC:

[0058] TEA (111 mg, 1.10 mmol, 154 μL, 1.20 eq) was added to a DMF (1.00 mL) solution of (19S)-19-ethyl-19-hydroxy-8-thioalkyl-17-oxa-3,13-diazapentane[11.8.0.02,11.04,9.015,20]docosa-1(21),2,4,6,8,10,15(20)-heptaen-14,18-dione (HS20189, 350 mg, 920 μmol, 1.00 eq) and dimethylarsine chloride (155 mg, 1.10 mmol, 1.20 eq). The mixture was stirred at 70°C for 2 hours. The reaction mixture was purified by preparative high-performance liquid chromatography (HPLC) (column: Phenomenex luna C18 150×40mm×15um; mobile phase: [water (TFA)-ACN]; gradient: 42%-72% B over 15 min). A yellow solid (19S)-8-dimethylarsylthio-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]docosa-1(21),2,4,6,8,10,15(20)-heptaen-14,18-dione (GMCTC, 48.89 mg, 91.48 μmol, 9.94% yield, 90.6% purity) was obtained. LCMS [M+1] + = 485.2; 1 HNMR(400MHz, DMSO-d6)δ = 9.12 (s, 1H), 8.11 (brd, J = 8.4 Hz, 1H), 7.88 (br d, J = 7.2 Hz, 1H), 7.80 (br t, J = 8.0 Hz, 1H), 7.36 (s, 1H), 5.44 (s, 2H), 5.33 (s, 2H), 1.93 - 1.81 (m, 3H), 1.44 (s, 6H), 0.89 (br t, J = 7.2 Hz, 3H).

[0059] Example 3, please refer to Figure 3 The compound shown is GMRA (JY20274): Synthesis of methyl N-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)noni-2,4,6,8-tetraenoyl)-S-(dimethylarsyl)-L-cysteine ​​ester.

[0060] Preparation of compound JY20274-3:

[0061] To a solution of (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)non-2,4,6,8-tetraenoic acid (1.00 g, 3.33 mmol, 1.00 eq.) in tetrahydrofuran (10.0 mL), CDI di(imidazol-1-yl) ketone (810 mg, 4.99 mmol, 1.50 eq.) was added. The mixture was stirred at 25°C for 0.5 h. Then, L-cysteine ​​methyl ester hydrochloride ((2R)-2-amino-3-sulfonylpropionate methyl ester hydrochloride) (857 mg, 4.99 mmol, 1.50 eq.) was added, and the mixture was stirred at 25°C for 1.5 h. The reaction mixture was diluted with water (20.0 mL) and extracted with dichloromethane (20.0 mL × 3). The combined organic layers were washed with brine (50.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the residue. The crude product was purified by reversed-phase HPLC (0.1% ammonium hydroxide) to give a yellow solid methyl((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexyl-1-en-1-yl)nona-2,4,6,8-tetraenoyl)-L-cysteine ​​ester (JY20274-3, 1.20 g, 2.87 mmol, 86.3% yield).

[0062] 1 HNMR(400 MHz, CDCl3) δ = 6.97 (dd, J = 11.2, 15.2 Hz, 1H), 6.34 (brd, J = 7.2 Hz, 1H), 6.27 (br d, J = 14.8 Hz, 2H), 6.19 - 6.10 (m, 2H), 5.77(s, 1H), 5.03 - 4.93 (m, 1H), 3.81 (s, 3H), 3.06 (dd, J = 4.0, 8.8 Hz, 2H), 2.37 (d, J = 0.8 Hz, 3H), 2.06 - 2.01 (m, 2H), 2.00 (s, 3H), 1.72 (s, 3H), 1.67 - 1.59 (m, 3H), 1.51 - 1.45 (m, 2H), 1.04 (s, 6H);

[0063] LCMS(ESI, m / z): [M+1] + = 418.3.

[0064] Preparation of compound GMRA (JY20274):

[0065] Triethylamine (851 mg, 8.41 mmol, 1.17 mL, 3.00 eq.) and dimethylarsine (1.18 g, 8.41 mmol / L, 3.00 equivalent) were added to a solution of methyl ((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexyl-1-en-1-yl)non-2,4,6,8-tetraenoyl)-L-cysteine ​​ester (1.17 g, 2.80 mmol, 1.00 eq.) in dichloromethane (10.0 mL). The mixture was stirred at 20°C for 16 hours. The reaction mixture was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 10 / 1, 1% V / V triethylamine) to give a yellow gel-like methyl N-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoyl)-S-(dimethylarsyl)-L-cysteine ​​ester (GMRA, 640 mg, 892 μmol, 31.8% yield, 82.7% purity).

[0066] 1 HNMR(400MHz, CDCl3) δ= 6.96 (dd, J = 11.6, 14.8 Hz, 1H), 6.35 - 6.21(m, 3H), 6.19 - 6.09 (m, 2H), 5.76 (s, 1H), 5.00 - 4.87 (m, 1H), 3.79 (s,3H), 3.26 - 3.14 (m, 2H), 2.37 (s, 3H), 2.02 (br d, J = 6.0 Hz, 2H), 2.00 (s,3H), 1.72 (s, 3H), 1.67 - 1.57 (m, 2H), 1.51 - 1.43 (m, 2H), 1.35 (d, J = 7.2 Hz (6H), 1.04 (s, 6H)

[0067] LCMS(ESI, m / z): [M+1] + = 522.3.

[0068] Example 4, please refer to Figure 4 The diagram shows the preparation of GMFC and GMYC.

[0069] Triethylamine (1.01 g, 2.0 mmol) and dimethylarsine chloride (0.21 g, 1.5 mmol) were added to an acetonitrile solution of cyclic peptide c (RGDfC) (0.58 g, 1.0 mmol). The mixture was stirred at room temperature for 16 hours. The solvent was then removed by vacuum distillation of the reaction mixture, and the solid distillate was washed with anhydrous dichloromethane to give a white solid product GMFC in 73% yield and 95% purity. LCMS[M+1] + = 683.2.

[0070] Triethylamine (1.01 g, 2.0 mmol) and dimethylarsine chloride (0.21 g, 1.5 mmol) were added to an acetonitrile solution of cyclic peptide c (RGDyC) (0.60 g, 1.0 mmol). The mixture was stirred at room temperature for 16 hours. Then, the reaction mixture was distilled off under reduced pressure to remove the solvent, and the solid distillate was washed twice with anhydrous dichloromethane to give 0.49 g of white solid product GMYC, yield 71%, purity 95%. LCMS[M+1] + = 699.2.

[0071] Example 5: Evaluation of the antitumor activity of four compounds, including GMCTC.

[0072] 1. Abstract.

[0073] This experiment mainly investigated the in vitro antitumor activity of four compounds: GMCTC, GMRA, GMYC, and GMFC. The IC50 of their antitumor activity was measured in colorectal cancer (HCT-116), hematologic malignancies (HL-60, K562, Molt-4), non-small cell lung cancer (A549, H1975, NCI-H522), melanoma (Malme-3M), prostate cancer (DU-145, PC-3), and breast cancer (MDA-MB-435).

[0074] 1.1 Positive control drug 1.

[0075] Name: Paclitaxel;

[0076] Source: MCE (HY-B0015);

[0077] Storage conditions: Store in a refrigerator at -20℃.

[0078] 1.2 Positive control drug 2.

[0079] Name: Imatinib (IM);

[0080] Source: MCE (HY-G0017);

[0081] Storage conditions: Store in a refrigerator at -20℃.

[0082] 1.3 Other reagents and materials.

[0083] Cell lines: Human acute lymphoblastic leukemia cells (Molt-4); human chronic myeloid leukemia cells (K562); human acute promyelocytic leukemia cell line (HL-60); human non-small cell lung cancer (A549); human non-small cell lung cancer (NCI-H522); human non-small cell lung cancer (H1975); human colon cancer cells (HCT-116); human breast cancer cells (MDA-MB-435); human prostate cancer cells (DU-145); human prostate cancer cells (PC-3); human melanoma cells (MALME-3M).

[0084] Culture media: RPMI 1640 medium, batch number: BL303A, Barsharp; DMEM medium: C11995500BT, Gibco; fetal bovine serum: AUS-01S-0-S, Cell-box; CCK8, 40203ES88, Yisheng Biotechnology.

[0085] 2. Experimental methods.

[0086] The CCK-8 assay was used to detect cell viability in 11 cancer cell lines using four compounds: GMCTC, GMRA, GMYC, and GMFC. After cells reached the logarithmic growth phase, they were trypsinized (suspension cells were not digested), resuspended, and seeded at a density of 3 × 10³ cells per well in 96-well plates. The cells were then incubated at 37°C with 5% CO₂ for 24 h. Working solutions of GMCTC, GMRA, GMYC, and GMFC at concentrations ranging from 0.13 to 300 μM were then added to the cell culture system, and the cells were cultured for another 48 h. After incubation, 10 μL of CCK-8 solution was added directly to each well, and the cells were incubated for another 2 h. The absorbance was then read at 450 nm using a microplate reader, and cell viability was calculated based on the absorbance data.

[0087] 3. Table of in vitro half-maximal inhibitory concentrations (IC50) of GMCTC, GMRA, GMFC, and GMYC against tumors. 50 ).

[0088]

[0089] Cell lines:

[0090] Human acute lymphoblastic leukemia cells (Molt-4); human chronic myeloid leukemia cells (K562); human acute promyelocytic leukemia cell line (HL-60).

[0091] Human non-small cell lung cancer (A549); Human non-small cell lung cancer (NCI-H522); Human non-small cell lung cancer (H1975); Human colon cancer cells (HCT-116);

[0092] Human breast cancer cells (MDA-MB-435); human prostate cancer cells (DU-145); human prostate cancer cells (PC-3); human melanoma cells (MALME-3M).

[0093] Experimental results: IC50 of GMCTC, GMRA, GMYC, and GMFC in prostate cancer (DU-145) 50 The values ​​were 0.7 μM, 7.5 μM, 1.3 μM, and 1.9 μM, respectively; the IC50 values ​​for PC3 cells were... 50 The values ​​were 3.8 μM, 77.3 μM, 12.9 μM, and 8.9 μM, respectively. IC50 values ​​for colorectal cancer (HCT-116) cells... 50 The values ​​were 1.1 μM, 15.5 μM, 2.5 μM, and 4.5 μM, respectively. The IC50 values ​​for leukemia cells (K562) were... 50 The values ​​were 0.5 μM, 2.2 μM, 0.8 μM, and 0.7 μM, respectively; the IC50 values ​​for leukemia cells (Molt-4) were... 50 The values ​​were 3.5 μM, 21.3 μM, 9.5 μM, and 17.7 μM, respectively; the IC50 values ​​for leukemia cells (HL-60) were... 50 The values ​​were 2.0 μM, 6.9 μM, 7.1 μM, and 9.3 μM, respectively. IC50 values ​​for non-small cell lung cancer (A549) cells... 50 The values ​​were 1.5 μM, 7.3 μM, 14.4 μM, and 4.6 μM, respectively; the IC50 values ​​for non-small cell lung cancer (H1975) cells were... 50 The values ​​were 81.2 uM, 108.4 uM, 84.3 uM, and 158.5 uM, respectively; the IC50 values ​​for non-small cell lung cancer (NCI-H522) cells were... 50 The values ​​were 2.9 μM, 3.5 μM, 4.7 μM, and 26.9 μM, respectively. The IC50 values ​​for melanoma (Malme-3M) cells were... 50 The values ​​were 0.6 μM, 6.7 μM, 5.7 μM, and 8.6 μM, respectively. IC50 of breast cancer (MDA-MB-435) cells. 50 The values ​​were 1.2uM, 7.1uM, 4.9uM, and 7.1uM, respectively.

[0094] Conclusion: All four compounds, GMCTC, GMRA, GMFC, and GMYC, have anti-tumor effects and have great potential for further development as anti-cancer drugs.

[0095] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. An organoarsenic compound or a pharmaceutically acceptable salt thereof, characterized in that, The compound has the structure shown in general formula (I): Formula (I) wherein, n is an integer from 0 to 10, and R1 is a C1-C20 alkyl group or a substituted alkyl group.

2. The organoarsenic compound according to claim 1, characterized in that, R1 is selected from methyl, ethyl, propyl, isopropyl, or butyl.

3. The organoarsenic compound of claim 1, wherein The compound is (S)-10-((dimethylarsenyl)thio)-4-ethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7] indo[1,2-b]quinoline-3,14(4H)-dione (GMCTC).

4. An organoarsenic compound or a pharmaceutically acceptable salt thereof, characterized in that, The compound is a compound represented by general formula (II): Formula (II) wherein, R is a C1-C20 alkylene chain, a substituted alkylene chain, an aryl group or a substituted aryl group, and its derivatives; R1 is a C1-C20 alkyl group or a substituted alkyl group.

5. The organoarsenic compound of claim 4, wherein, R1 is selected from methyl, ethyl, propyl, isopropyl, or butyl; -NH-RS- Selected from:

6. The organoarsenic compound of claim 4, wherein, The compound is methyl N-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)noni-2,4,6,8-tetraenoyl)-S-(dimethylarsyl)-L-cysteine ​​ester (GMRA).

7. An organoarsenic compound or a pharmaceutically acceptable salt thereof, characterized in that, The compound is a compound represented by general formula (III): Formula (III) wherein Cyclo-peptide represents a cyclic peptide; R is C1-C20 alkyl, substituted alkyl.

8. The organoarsenic compound according to claim 7, characterized in that, The cyclic peptide is selected from the group consisting of the following sequences: cyclo(Arg-Gly-Asp-D-Phe-Cys) [c(RGDfC)], cyclo(Arg-Gly-Asp-D-Tyr-Cys) [c(RGDyC)], cyclo(Arg-Gly-Asp-D-Phe-Lys(COCH2CH2SH)) [c(RGDfK(Mpa))], cyclo(Arg-Gly-Asp-D-Phe-Lys(COCH2SH)) [c(RGDfK(COCH2SH))], cyclo(Arg-Gly-Asp-D-Phe-Lys(Cys)) [c(RGDfK(Cys))].

9. The organoarsenic compound according to claim 7, characterized in that, The compound has the structure shown in general formula (IV): General formula (IV) in which, R1 is selected from methyl, ethyl, propyl, isopropyl, or butyl; R2 is selected from hydrogen, halogen, alkyl, alkoxy, hydroxyl, amino, carboxyl, cyano, or nitro.

10. The organoarsenic compound according to claims 7 and 9, characterized in that, The compound is GMFC, GMYC:

11. A method for preparing organoarsenic compounds of general formulas (I) to (IV) as described in claims 1 to 10, characterized in that, The method uses dimethylarsine chloride as an arsenicizing agent, which is prepared by dissolving dimethylarsine in concentrated hydrochloric acid, reacting it with a mixture of hypophosphoric acid and hydrochloric acid, and then purifying it.

12. Use of the pharmaceutical composition of any one of claims 1 to 10, containing an organic arsenic compound, in the preparation of a medicament for treating cancer; The cancers mentioned are selected from leukemia, lymphoma, lung cancer, skin cancer, prostate cancer, colorectal cancer, breast cancer, esophageal cancer, liver cancer, stomach cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, or cervical cancer.